What Is Rybelsus?
Rybelsus is an oral tablet form of semaglutide — the same active ingredient found in Ozempic and Wegovy. It was FDA-approved in September 2019 for the treatment of Type 2 diabetes, making it the first oral GLP-1 receptor agonist ever approved. While not currently FDA-approved for weight management, it is sometimes prescribed off-label for that purpose.
How Oral Semaglutide Works Differently
Semaglutide is a peptide that would normally be broken down by stomach acid before it could be absorbed. Rybelsus overcomes this by combining semaglutide with an absorption enhancer called SNAC, which temporarily raises local pH in part of the stomach and allows the drug to be absorbed through the stomach lining.
Because of this mechanism, Rybelsus must be taken very specifically: on an empty stomach, first thing in the morning, with no more than four ounces of plain water, at least 30 minutes before eating, drinking, or taking other medications.
Efficacy Compared to Injectable Semaglutide
Rybelsus produces meaningful improvements in blood sugar control and modest weight loss, but its efficacy is generally lower than injectable semaglutide at comparable doses — primarily due to lower and more variable bioavailability. For patients who strongly prefer to avoid injections, Rybelsus offers a meaningful option, but injectable semaglutide or tirzepatide typically outperform for maximum weight loss efficacy.
Common Side Effects
- Nausea — similar profile to injectable semaglutide
- Diarrhea and constipation
- Stomach pain and decreased appetite
The Future of Oral GLP-1
Eli Lilly is in Phase 3 trials for orforglipron, a non-peptide oral GLP-1 agonist that does not require fasting before taking. If approved, it could offer the convenience of a daily pill without Rybelsus's strict administration requirements — potentially making oral GLP-1 therapy far more accessible.